Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0002871 (anemia)
 52,094 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 53-year-old white woman developed diabetes mellitus, migratory erythema, and anemia, clinical features suggesting the presence of a "glucagonoma." Ten years earlier, after laparotomy and pancreatic biopsy, she had been told that she had an inoperable pancreatic carcinoma. Review of that biopsy together with current hormonal assay now confirms the diagnosis of glucagonoma. The recurrent peptic ulcer in this patient despite high levels of glucagon, a gastric inhibitory agent, is noted but not explained. An enhanced amylase-creatinine clearance ratio supports the notion that glucagon increases the clearances of amylase.
 ...
PMID:Glucagonoma, chronic recurrent peptic ulcer disease, and enhanced amylase-creatinine clearance ratio. Report of a case with review of the literature. 9 10

Reduced carbon monoxide diffusing capacity of the lung (DLCO) is reported in patients with impaired renal function. Since DLCO also depends on the pulmonary capillary blood volume the role of renal anaemia was evaluated. Measurements were carried out in 43 azotaemic patients [serum creatinine (SKr) 1.5 to 14.0 mg/100 ml], without evidence of cardiovascular or pulmonary complications of uraemia, of SKr, haemoglobin concentration (Hb) and steady state DLCO. In the case of DLCO values allowance was made for body surface area and thoracic gas volume. The relation was studied of the corrected DLCO to SKr and to Hb. There was a higher statistical correlation between DLCO and Hb than between DLCO and SKr. After additional correction of DLCO for Hb, no correlation to SKr was found. It is concluded that the reduction in DLCO in uraemia is due largely to a low Hb and, hence, to renal anaemia rather than to uraemic damage of interstitial lung tissue.
 ...
PMID:[Renal failure and carbon monoxide diffusing capacity of the lung (author's transl)]. 42 39

By use of the fetal mouse liver cell assay, serum erythropoietin (SEp) concentration was measured in 135 patients at various stages of chronic renal failure and in 59 healthy subjects. In patients with creatinine clearances (CCr) ranging from 2 to 40 ml/min/1.73 sq m, endocrine renal function was found to deteriorate in parallel to excretory renal function. The known negative correlation between SEp and hematocrit (Hct) was not apparent, probably because of the loss of renal mass accompanying progress of anemia and renal insufficiency. In contrast, in patients with minimal variation of residual excretory renal function, as in individual patients investigated repeatedly within a short period of time, changes of Hct were always accompanied by opposite changes of corresponding SEp concentrations. Thus, patients with chronic renal failure have a sustained regulatory feedback mechanism between Hct and SEp, which probably works at a lower level.
 ...
PMID:Serum erythropoietin concentration in chronic renal failure: relationship to degree of anemia and excretory renal function. 47 5

Dose-response relationships between blood lead levels and toxic effects have been evaluated in 160 lead workers in two smelters and a chemicals plant. Blood lead levels ranged from 0.77 to 13.51 mumol/litre (16-280 microgram/dl). Clinical evidence of toxic exposure was found in 70 workers (44%), including colic in 33, wrist or ankle extensor muscle weakness in 12, anaemia (Hgb less than 8.69 mumol/litre (Hb/4) or 14.0 gm/dl) in 27, elevated blood urea nitrogen (greater than or equal to 7.14 mmol/litre or 20 mg/dl) in 28, and possible encephalopathy in two. No toxicity was detected at blood lead levels below 1.93 mumol/litre (40 microgram/dl). However, 13% of workers with blood lead levels of 1.93 to 3.81 mumol/litre (40-79 microgram/dl) had extensor muscle weakness or gastrointestinal symptoms. Anaemia was found in 5% of workers with lead levels of 1.93-2.85 mumol/litre (40-59 microgram/dl), in 14% with levels of 2.90 to 3.81 mumol/litre (60-79 microgram/dl), and in 36% with levels greater than or equal to 3.86 mumol/litre (80 microgram/dl). Elevated blood urea nitrogen occurred in long-term lead workers. All but three workers with increased blood urea nitrogen had at least four years occupational lead exposure, and nine had received oral chelation; eight of this group had reduced creatinine clearance, and eight had decreased renal concentrating ability. These data support the establishment of a permissible biological limit for blood lead at a level between 1.93 and 2.90 mumol/litre (40-60 microgram/dl).
 ...
PMID:Occupational lead poisoning in the United States: clinical and biochemical findings related to blood lead levels. 50 43

Despite the high frequency of skeletal metastases from cancer of the prostate, hypercalcaemia is extremely uncommon in this condition. In two patients with advanced, poorly differentiated metastasizing cancer a fairly uniform clinical picture developed, with anaemia, leukocytosis, increased serum creatinine, thrombocytopenia, elevated alkaline and acid phosphatase levels and symptoms secondary to hypercalcaemia. The development of more effective agents against cancer of the prostate will probably afford longer palliation, but evidently at a risk of severe metabolic disturbances in the preterminal state.
 ...
PMID:Advanced cancer of the prostate combined with hypercalcaemia. 59 76

During the last 3 years 3,964 short daily peritoneal dialyses (71.4% at home) have been performed in 18 patients aged between 8 and 82 years. 6-10 liters of dialysate have been associated with high caloric-low protein (0.6 g/kg) diets. In 330 predialysis determinations serum urea was 1.30 +/- 0.09 g/l and serum creatinine was 13.9 +/- 1.9 mg/dl. The incidence of peritonitis was 0.18%. The control of anemia, plasma levels of proteins, albumins, transferrin, C-3c and C-4 were satisfactory. The data support the concept of a wider application of this dialysis technique, which may be extended to every uremic patient.
 ...
PMID:Short daily peritoneal dialysis: 3 years' experience. 67 96

Considerable evidence suggests that insufficient EP production and the presence of a toxic factor inhibiting erythropoiesis are two major factors responsible for the production of anemia in patients with CRF. The toxic factor can be detected in a number of tissue culture systems. In order to evaluate its mechanism of action in a proliferation-dependent system, we studied the formation of erythroid colonies in plasma clots containing normal serum and CRF serum, using normal mouse marrow cells as the target organ. Fewer colonies were found in cultures containing uremic serum. This effect was greater as the concentration of serum was increased. No differences were found in the size or morphology of colonies formed. Addition of urea and creatinine to normal sera did not affect their ability to support colony growth. Uremic sera had no effect on white cell colony growth in the plasma clot system. We conclude that materials inhibitory to erythroid proliferation are present in CRF serum.
 ...
PMID:The effect of serum from patients with chronic renal failure on erythroid colony growth in vitro. 68 22

Eighteen patients with advanced squamous cell cancer of the head and neck were treated with cis-diamminedichloroplatinum in a 24-hour infusion. The most frequent dose used was 80 mg/m2 repeated every three weeks. Six were treated preoperatively for Stage III or IV disease, and twelve were treated for recurrent disease. The overall response rate was 72% with one complete remission, greater than 50% regression in six patients, and 25--50% regression in six patients. Toxicity was minimal: creatinine greater than 2 in 6% of courses, leukopenia in 9%, anemia in 29%, vomiting in 76%, and documented minimal hearing loss in one patient. Plasma and urine platinum levels during infusion are presented. The dosage of 80 mg/m2 administered over 24 hours gives a response rate in head and neck cancers equivalent to that reported with higher doses given by rapid infusion, and toxicity is minimal.
 ...
PMID:24-hour infusion of cis-platinum in head and neck cancers. 71 1

In patients who are receiving chronic hemodialysis treatments, concentrations of creatinine and uric acid in serum correlated significantly with those in simultaneously drawn unstimulated whole saliva, both before and after dialysis. Similar correlation was shown also in a group of moderately azotemic patients who had not yet entered the chronic hemodialysis program. Use of whole saliva in these tests instead of blood samples may reduce the iatrogenic component in anemia, the frequency of venipunctures and of blood samplings. This may be a boon particularly in pediatric patients and in other patients where, due to a variety of reasons, this is desirable.
 ...
PMID:Correlation of biochemical parameters in serum and saliva in chronic azotemic patients and patients on chronic hemodialysis. 72 95

A number of potentially toxic compounds accumulate in the sera of patients with end-stage renal disease, and some have been demonstrated to inhibit erythropoiesis. In vitro CFU-E and BFU-E erythroid colony growth was compared in the presence of sera from patients with anemia of renal insufficiency and normal human subjects with the use of plasma clot cultures of normal rabbit bone marrows. In studies of sera from nine undialyzed patients with anemia of renal insufficiency and seven normal human subjects, all undialyzed sera from the anemic uremic patients produced a significant (p less than 0.001) inhibition of both CFU-E and BFU-E. A marked reduction in the inhibitor of CFU-E was seen in the sera of three out of four patients following intermittent hemodialysis. Creatinine, guanidine hydrochloride, guanidinosuccinic acid, and guanidinobutyric acid did not affect the number of CFU-E in normal rabbit bone marrow cultures. These data suggest that uremic toxins in the sera of undialyzed anemic uremic patients inhibit erythropoiesis, are partially removed by regular hemodialysis, and may play an important role in the mechanism of the anemia associated with renal insufficiency. These inhibitors of CFU-E do not appear to be creatinine or guanidine derivatives.
 ...
PMID:Inhibitors of erythroid colony-forming cells (CFU-E and BFU-E) in sera of azotemic patients with anemia of renal disease. 73 70


1 2 3 4 5 6 7 8 9 10 Next >>